Featured Press Releases

ImmunityBio Announces FDA Approval of ANKTIVA®,

ImmunityBio Announces FDA Approval of ANKTIVA®,

CollPlant

CollPlant's Collink.3D® BioInks and Technologies Provide a Timely Alternative to Animal Testing in Line with FDA's New Preclinical Guidelines

  • 15 Apr 2025

CollPlant Biotechnologies, a regenerative and aesthetics medicine company developing innovative...

Supporting the lab of the future, MilliporeSigma partners with Opentrons Labworks, Inc

Supporting the lab of the future, MilliporeSigma partners with Opentrons Labworks, Inc

Brainomix

Brainomix's AI-Powered e-Lung, Developed with AstraZeneca, Improves Identification of Lung Fibrosis Patients at Risk

Zafrens expands its investor syndicate to scale its revolutionary drug discovery platform

Zafrens expands its investor syndicate to scale its revolutionary drug discovery platform

AdvanCell Proudly Announces $18M in MRFF Frontiers Initiative Funding to Advance Targeted Alpha Therapy for Defeating Prostate Cancer

AdvanCell Proudly Announces $18M in MRFF Frontiers Initiative Funding to Advance Targeted Alpha Therapy for Defeating Prostate Cancer

Johnson & Johnson Strengthens European Cardiac Care with the Introduction of the Dual Energy THERMOCOOL SMARTTOUCH SF Ablation Platform

Johnson & Johnson Strengthens European Cardiac Care with the Introduction of the Dual Energy THERMOCOOL SMARTTOUCH SF Ablation Platform

  • Johnson & Johnson
  • 25 Jun 2026
StatLab Introduces CytoPath Disc, Enhancing Global Standards in Cell Block Preparation

StatLab Introduces CytoPath Disc, Enhancing Global Standards in Cell Block Preparation

  • StatLab Medical Products
  • 25 Jun 2026
FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

  • Ionis Pharmaceuticals, Inc.
  • 24 Jun 2026
FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

FDA Grants Approval to TRYNGOLZA® (olezarsen) for the Treatment of Severe Hypertriglyceridemia, Marking a First-in-Class Milestone

  • Ionis Pharmaceuticals, Inc.
  • 24 Jun 2026
Zeta Surgical® has announced the successful treatment of the first patient using its Zeta TMS Navigation System at HOPE Therapeutics.

Zeta Surgical® has announced the successful treatment of the first patient using its Zeta TMS Navigation System at HOPE Therapeutics.

  • Zeta Surgical
  • 23 Jun 2026
Upsher-Smith Expands KYMBEE™ (Deflazacort) Family of Products with Launch of Oral Suspension for the Treatment of Duchenne Muscular Dystrophy

Upsher-Smith Expands KYMBEE™ (Deflazacort) Family of Products with Launch of Oral Suspension for the Treatment of Duchenne Muscular Dystrophy

  • Upsher-Smith Laboratories, LLC
  • 23 Jun 2026
The Digital Pharma Advances Conference 2026

Most Popular
June   2026
M T W T F S S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.